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Background:  Almost  all  data  on  drug-eluting  stents  (DES)  fracture  have been  derived  from  initial  platform
of  ﬁrst-generation  DES  such  as  Cypher  Bx® (CBX)  and  Taxus  Express®. However,  incidence  and  clinical
impact  of  fracture  of newer  DES  platforms  (including  Cypher  Select®, Taxus® LibertéTM, Endeavor®,  and
XienceTM V)  that  have  been  used  widely  in current  clinical  practice  have  not  yet  been  studied.
Methods  and  results:  We  analyzed  data  of  1518  lesions  treated  with  the  newer  DES  platforms  in patients
who  underwent  follow-up  coronary  angiography  and  compared  the  results  with  those  of  622  lesions
treated  with  the CBX.  The  group  of  newer  DES  platforms  showed  signiﬁcantly  lower  incidence  of  stent
fracture  (SF)  than  the  CBX  group  (1.25%  vs.  5.8%,  p <  0.001).  Binary  restenosis  (42.1%  vs.  6.6%,  p <  0.001)  and
target  lesion  revascularization  (TLR)  (47.3%  vs.  6.2%,  p <  0.001)  related  to  SF  in the newer  DES platforms’
group  were  signiﬁcantly  higher  than  those  not  related  to  SF.  Notably,  SF-related  binary  restenosis  (42.1%
vs. 36.1%,  p  =  0.52)  and  TLR  (47.3%  vs.  41.6%,  p =  0.2)  were  similar  between  the newer  DES  platforms’  group
and the  CBX  group.  On  multivariable  logistic  regression  analysis,  lesion  angulation  >45◦ (odds  ratio  [OR]:
7.6;  95%  conﬁdence  interval  [CI]:  2.2–26.31),  RCA  stenting  (OR:  5.14;  95%  CI: 1.62–16.3) and  total  stent
length  (OR:  1.18;  95% CI: 1.03–1.33)  were  identiﬁed  as  independent  predictors  for fracture  of  the  newer
DES  platforms,  while  closed-cell  design  stent  (Cypher  Select®) was  not.
Conclusions:  Although  implantation  of  the  newer  DES  platforms  might  reduce  the  occurrence  of  SF  com-
pared  with  the CBX,  SF-related  binary  restenosis  and  TLR  remain  similarly  high.  And to  predict  SF in the
newer DES  platforms’  era,  lesion  characteristics  on  index  procedure  are  more  important  than  implanted
stent design.
2  Jap©  201
ntroduction
Although stent fracture (SF) is an uncommon complication of
rug-eluting stents (DES), its occurrence may  be associated with
linically serious complications such as restenosis, stent throm-
osis, and aneurysm formation. Several studies have reported
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on the incidence, predictors, and clinical impact of DES frac-
ture [1–3]. However, when we reviewed previous reports, almost
all data on DES fracture were derived from the initial plat-
form of ﬁrst-generation DES, mainly from the initial platform of
sirolimus-eluting stent [i.e. Cypher Bx® (CBX), Cordis, Johnson
and Johnson Corp., Miami, FL, USA] and paclitaxel-eluting stent
(i.e. Taxus Express®, Boston Scientiﬁc Corp., Natick, MA,  USA)
[1–3].In current clinical practice, the majority of physicians have per-
formed percutaneous coronary intervention (PCI) using newer DES
platforms, such as Cypher Select® (CS) (Cordis, Johnson and Johnson
Corp.)/Taxus® LibertéTM (TL) (Boston Scientiﬁc Corp.)/Endeavor®
vier Ltd. All rights reserved.
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EN) (Medtronic Cardiovascular, Minneapolis, MN,  USA)/XienceTM
 (XV) (Abbott Vascular, Abbott Park, IL, USA) rather than the ini-
ial platforms of ﬁrst-generation DES. Although the newer DES
latforms have been upgraded in terms of both mechanical and
aterial properties, clinical information on SF remains to be deter-
ined. This is in contrast to the well-known dataset of initial
latforms of ﬁrst-generation DES. We  identiﬁed the incidence, pre-
ictors, and clinical impact of fracture in newer DES platforms
ncluding CS, TL, EN, and XV, and compared results with those of
nitial platform of ﬁrst-generation CBX as a control group.
ethods
tudy population and procedure
We  retrospectively analyzed data from the Catholic Medi-
al Center Percutaneous Coronary Intervention (COACT) registry,
hich is a multicenter, observational, all-comers registry of 9292
atients who underwent PCI with DES at 8 participating hospitals
rom September 2003 to December 2009. This study complied with
he Declaration of Helsinki regarding investigation in humans and
as approved by the institutional ethics committees at the partici-
ating hospitals. Written informed consent was obtained from each
atient before enrollment. There was no industry involvement in
he design, conduct, or analysis of the study. Of 1048 PCI patients
ith CBX, we analyzed available data for 622 consecutive lesions
n 518 patients who underwent follow-up coronary angiography
CAG). We  also identiﬁed a total of 4664 stented lesions treated
ith newer DES platforms in 4104 patients and of these, ana-
yzed clinical and angiographic data of 1518 consecutive lesions
n 1224 patients who underwent follow-up CAG. Follow-up CAG
as performed irrespective of clinical symptoms and was  routinely
ecommended 6–12 months after index procedure unless clini-
ally necessary at an earlier time. The majority (94.5%) of enrolled
atients underwent follow-up CAG routinely. Some patients under-
ent several times of follow-up CAG; in these cases, we calculated
 follow-up duration from index PCI to ﬁnal repeat angiography.
ll interventions were performed according to standard guidelines.
ll patients were prescribed aspirin (100–325 mg/day) indeﬁnitely
nd clopidogrel (300–600 mg  loading dose, 75 mg  daily for at least
ix months). All CAG were reviewed by two experienced cardi-
logists blinded to clinical information. The SF was  diagnosed
n ﬂuoroscopy or angiography, and intravascular ultrasound was
ot mandatory. To visualize stent strut effectively, we used the
ncreased magniﬁcation, image without contrast and image with
nverted color for all stented lesions. Quantitative coronary analy-
is (QCA) was performed using the computer-based edge-detection
oronary Angiography Analysis System (CAAS 5.7, Pie Medical,
aastricht, The Netherlands). SF was classiﬁed as either complete
racture (complete separation of stent segments) or partial frac-
ure (single or multiple stent SF without separation of segment)
1]. Binary restenosis was  deﬁned as a reduction of 50% or more
f the luminal diameter in the stented segment (in-stent) and
he margins 5 mm proximal and distal to the stent (in-segment)
t follow-up. Target lesion revascularization (TLR) was  deﬁned as
epeated revascularization for ischemia owing to in-stent or in-
egment restenosis.
tatistical analysis
Statistical analysis was  performed using SPSS 15.0 (SPSS Inc.,
hicago, IL, USA). Continuous variables except follow-up duration
ere presented as mean (±SD) and compared using Student’s t-test.
ategorical variables were presented as frequencies or percent-
ges and compared using chi-square test or Fisher’s exact test. Weiology 60 (2012) 215–221
compared the median follow-up duration of each group using
Mood’s median test. To determine the independent predictors of
SF in CBX group and newer DES platforms’ group respectively,
multivariable logistic regression analysis was  used. Independent
variables were selected according to their weight on univariate
testing for entry into the multivariate model (p-values < 0.1 in
Table 2) and well-known established predictors (closed-cell design:
Cypher Select® in the newer DES platforms’ group, right coronary
artery [RCA] stenting in CBX group) were also entered into the anal-
ysis. We  calculated odds ratio (OR) of CBX-to-newer DES platforms
for SF using multivariable logistic regression analysis, for which,
we merged data from both groups and introduced into the model
variables that showed signiﬁcant difference between patients with
SF and without SF (age, RCA stenting, total stent length, stent type
[CBX vs. newer DES platforms], lesion angulation >45◦) (data not
shown). A p-value of <0.05 was considered to indicate a signiﬁcant
difference.
Results
Clinical and angiographic characteristics of stent fracture
Baseline clinical and angiographic characteristics between the
newer DES platforms’ group and the CBX group are listed in Table 1.
Patients in newer DES platforms’ group had a younger age, longer
lesion length, longer total stent length, and lower rates of binary
restenois and TLR compared to CBX group. We  also compared base-
line characteristics between SF subgroup and non-SF subgroup
(Table 2). In the newer DES platforms’ group, patients with SF
showed a higher incidence of previous myocardial infarction (MI)
and coronary artery bypass graft history compared to patients in
whom SF did not occur. SF mainly occurred in the RCA and the left
anterior descending artery (LAD); however, no SFs were observed
in the left circumﬂex artery (LCX). Compared with the non-SF sub-
group, lesions in the SF subgroup showed more B2/C type, smaller
reference diameter, longer lesion length, higher incidence of lesion
angulation >45◦, longer total stent length, more number of stents
per lesion, and higher frequency of stent overlap. In CBX group,
lesions in the SF subgroup showed more B2/C type, longer lesion
length, higher incidence of lesion angulation >45◦, longer total stent
length, more number of stents per lesion, and higher frequency of
stent overlap compared with lesions in the non-SF subgroup. In
addition, comparisons of baseline characteristics between SF sub-
groups in the newer DES platforms’ group and the CBX group are
listed in Table 3.
Incidence of stent fracture
The median follow-up duration from index PCI to detection of
SF was similar between the newer DES platforms’ group and the
CBX group (12.5 months [interquartile range [IQR]: 9.2–15.5] vs.
9.5 months [IQR: 6.3–13], p = 0.11) (Table 3). SF was identiﬁed in
36 of 622 lesions (5.8%) and 518 patients (6.9%) in the CBX group,
and 19 of 1518 lesions (1.25%) and 18 of 1224 patients (1.47%) in
the newer DES platforms’ group. Notably, the incidence of SF in the
CBX group was  signiﬁcantly higher than that of the newer DES plat-
forms’ group (5.8% vs. 1.25%, p < 0.001) (Fig. 1). Of the 1518 lesions
in the newer DES platforms’ group, 635 lesions in 508 patients
were implanted with CS, 411 lesions in 329 patients with TL, 110
lesions in 88 patients with EN, and 362 lesions in 299 patients
with XV. Eleven SFs were identiﬁed in the CS group (1.7%), 4 in
the TL group (0.97%), 0 in the EN group (0%), and 4 in the XV group
(1.1%); with the incidence being similar among stent types (p = 0.15)
(Fig. 1). Detailed individual patient data for the 19 SF cases in the
newer DES platforms’ group are provided in Supplementary Table 1.
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Table  1
Baseline clinical and angiographic characteristics.
Clinical characteristics (n = no. of patients) Newer DES platforms (n = 1224) Cypher Bx (n = 518) p
Age, years 64.4 ± 10.1 67.5 ± 7.4 0.04
Male,  n (%) 869 (70.9) 327 (63.1) 0.12
BMI  (kg/m2) 24.3 ± 2.8 24.5 ± 2.1 0.52
Index  diagnosis, n (%)
Stable angina 477 (38.9) 20 (41.7) 0.58
Unstable angina 227 (18.5) 111 (21.4) 0.65
AMI  363 (29.6) 147 (28.3) 0.77
Silent  ischemia 179 (14.6) 44 (8.4) 0.43
Diabetes mellitus, n (%) 398 (32.5) 182 (35.1) 0.58
Hypertension, n (%) 739 (60.3) 387 (74.7) 0.33
Current smoking, n (%) 386 (31.5) 140(27) 0.64
Family history of CAD, n (%) 150 (12.2) 66 (12.7) 0.81
Previous MI, n (%) 109 (8.9) 54 (10.4) 0.72
Previous CABG, n (%) 6 (0.4) 3 (0.5) 0.88
LVEF  (%) 60.4 ± 8 58.7 ± 12 0.55
Angiographic characteristics (n = no. of lesions) Newer DES platforms (n = 1518) Cypher Bx (n = 622) p
Target coronary artery, n (%)
LM 34 (2.2) 4 (0.6) 0.21
LAD  715 (47.1) 212 (34) 0.45
LCX 415 (27.3) 139 (22.3) 0.74
RCA  354 (23.3) 167 (26.8) 0.66
AHA/ACC type B2/C, n (%) 882 (58.1) 356 (57.2) 0.87
Reference diameter (mm)  3.28 ± 0.3 3.34 ± 0.3 0.16
Lesion length (mm)  35.1 ± 15 30.1 ± 9 0.03
Diameter stenosis (%) 81± 15 78± 10 0.63
Lesion angle >45◦ , n (%) 184 (12.1) 79 (12.7) 0.77
CTO,  n (%) 87 (5.7) 45 (7.2) 0.41
Multivessel CAD, n (%) 1002 (66) 398 (63.9) 0.38
Stent  diameter (mm)  3.1 ± 0.27 3.12 ± 0.26 0.11
Maximum inﬂation pressure (atm) 14.6 ± 2.7 13.9 ± 2.5 0.58
Total  stent length (mm) 37.3 ± 14.2 33.2 ± 10.3 0.02
Number of stents per lesion 1.18 ± 0.6 1.11 ± 0.4 0.65
Stent  overlap, n (%) 288 (18.9) 70 (11.2) 0.41
Clinical outcome at follow-up, n (%)
Binary restenosis 107 (7) 74 (11.9) <0.001
TLR  102 (6.7) 55 (8.8) 0.007
Values are expressed as mean ± SD or n (%) of patients.
ACC, American College of Cardiology; AHA, American Heart Association; AMI, acute myocardial infarction; BMI, body mass index; CABG, coronary artery bypass graft; CAD,
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requencies of occurrence of partial and complete SF were similar
47.4% vs. 52.6%). While in single-stented lesions, the majority of
F were localized to the middle portion of the stent body (75%),
n overlapping stents, most fractures were observed within 5-mm
ig. 1. Incidence of stent fracture according to stent type. Incidence of stent frac-
ure  of the CBX group (blue color) was signiﬁcantly higher than that of the newer
ES  platforms’ group (orange color). Among the newer DES platforms’ group, no
ifferences were shown in incidence of stent fracture. CBX, Cypher Bx®; CS, Cypher
elect®; TL, Taxus® LibertéTM; EN, Endeavor®; XV, XienceTM V; DES, drug-eluting
tents. *Entire population of newer DES platforms’ group. (For interpretation of the
eferences to color in this ﬁgure legend, the reader is referred to the web version of
he  article.)rug-eluting stents; IQR, interquartile range; LAD, left descending artery; LCX, left
; MI,  myocardial infarction; PCI, percutaneous coronary intervention; RCA, right
from areas of metal overlap (90.5%). All SFs occurred in long-stented
lesions, i.e. ≥28 mm,  and the longest stented lesion was  82 mm.  A
sizable proportion of SFs occurred at the biggest angle (hinge point)
at index CAG (63%).
Clinical impact of stent fracture
In the newer DES platforms’ group, a large portion of patients
with SF were asymptomatic (61.1%) and some patients presented
clinically with stable (33.3%) or unstable angina (10.5%) when
SF was detected by angiography. Neither myocardial infarction
nor stent thrombosis occurred (Table 3). While SF-related binary
restenosis (42.1% vs. 6.6%, p < 0.001) and TLR (47.3% vs. 6.2%,
p < 0.001) rates were signiﬁcantly higher than those related with
non-SF, overall incidence of binary restenosis and TLR among stent
types was  similar (Fig. 2). It is interesting that all binary resteno-
sis related to SF was  observed within stent (i.e. in-stent restenosis)
with focal angiographic pattern. In the CBX group, a large portion
of patients with SF were also asymptomatic (58.3%) at the time of
SF detection (Table 3) and incidence of binary restenosis (36.1% vs.
10.4%, p = 0.006) and TLR (41.6% vs. 6.8%, p < 0.001) related with SF
was signiﬁcantly higher than that related with non-SF (Table 2). It
is notable that SF-related binary restenosis and TLR rates of the CBX
group were similar when compared with those of the CS group and
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Table 2
Comparisons of baseline characteristics between fracture subgroup and non-fracture subgroup.
Clinical characteristics (n = no. of patients) Newer DES platforms p Cypher Bx p
Fracture (n = 18) Non-fracture (n = 1206) Fracture (n = 36) Non-fracture (n = 482)
Age, years 63.7 ± 10.5 65.2 ± 9.3 0.72 67.9 ± 6.8 66.7 ± 9.7 0.62
Male,  n (%) 13 (72.2) 856 (70.9) 0.98 24(67) 303(63) 0.86
BMI  (kg/m2) 24.1 ± 2.8 24.6 ± 2.8 0.46 24.3 ± 1.9 24.7 ± 2.5 0.52
Index  diagnosis, n (%)
Stable angina 10 (55.5) 467 (38.7) 0.35 20 (55.5) 196 (40.7) 0.43
Unstable angina 4 (22.2) 223 (18.5) 0.76 9(25) 102 (21.2) 0.64
AMI  3 (16.6) 360 (29.8) 0.24 7 (19.4) 140 (29) 0.55
Silent  ischemia 2 (11.1) 177 (14.6) 0.87 0(0) 44 (9.1) 0.77
Diabetes mellitus, n (%) 5 (27.7) 393 (32.5) 0.67 11 (30.5) 171 (35.5) 0.6
Hypertension, n (%) 15 (83.3) 724 (60) 0.1 31 (86) 356 (74) 0.33
Current smoking, n (%) 6 (33.3) 380 (31.5) 0.85 9 (25) 131 (27.2) 0.75
Family history of CAD, n (%) 3 (16.6) 147 (12.1) 0.88 4 (11.1) 62 (12.8) 0.81
Previous MI,  n (%) 5 (27.7) 104 (8.6) 0.02 4 (11.1) 50 (10.4) 0.72
Previous CABG, n (%) 1 (5.5) 5 (0.4) 0.006 0 (0) 3 (0.6) 0.68
LVEF  (%) 61 ± 7 59 ± 10 0.43 59 ± 14 58 ± 10 0.55
Median follow-up duration months (IQR) 12.5 (9.2–15.5) 9 (6.2–13.1) 0.007 9.5 (6.3–13) 11 (8.2–15.4) 0.23
Angiographic characteristics (n = no. of lesions) Newer DES platforms p Cypher Bx p
Fracture (n = 19) Non-fracture (n = 1499) Fracture (n = 36) Non-fracture (n = 586)
Target coronary artery, n (%)
LM 1 (5.2) 33 (2.2) 0.64 0 4 (0.7) 0.87
LAD  8 (42) 707 (47.2) 0.82 22 (61) 290 (49.5) 0.45
LCX  0 415 (27.6) 0.03 1 (2.7) 138 (23.5) 0.21
RCA 10 (52.6) 344 (22.9) 0.05 13 (36) 154 (26.3) 0.13
AHA/ACC type B2/C, n (%) 19 (100) 863 (57.5) 0.001 34 (94) 322 (55) 0.001
Reference diameter (mm) 3.18 ± 0.3 3.37 ± 0.4 0.01 3.4 ± 0.3 3.28 ± 0.3 0.06
Lesion length (mm) 45.5 ± 16.2 24.7 ± 13 <0.001 36.5 ± 9.9 23.6 ± 10 <0.001
Diameter stenosis (%) 79 ± 24 85 ± 11 0.33 75 ± 10 81 ± 11 0.43
Lesion angle >45◦ , n (%) 7 (36.8) 177 (11.8) 0.007 21 (58) 58 (9.9) 0.002
CTO,  n (%) 3 (15.8) 84 (5.6) 0.1 1 (2.7) 44 (7.5) 0.28
Multivessel CAD, n (%) 15 (78.9) 987 (65.8) 0.29 22 (61) 376 (64.2) 0.57
Stent diameter, mm 2.97 ± 0.32 3.2 ± 1.0 0.29 3.18 ± 0.26 3.06 ± 0.28 0.06
DES  type, n (%)
Cypher Select 11 (57.9) 625 (41.7) 0.58
Taxus Liberté 4 (21) 407 (27.1) 0.68
Endeavor 0 110 (7.3) 0.74
Xience V 4 (21) 358 (23.9) 0.75
Maximum inﬂation pressure (atm) 14.3 ± 2.6 15 ± 3.6 0.32 13.6 ± 2.5 14.2 ± 2.7 0.44
Total  stent length (mm)  48.3 ± 16.8 26.3 ± 13.2 <0.001 41.2 ± 10.9 25.2 ± 10.2 <0.001
Number of stents per lesion 1.58 ± 0.6 1.18 ± 0.4 0.001 1.53 ± 0.7 1.08 ± 0.4 0.001
Stent overlap, n (%) 11 (57.9) 277 (18.5) <0.001 19 (53) 51 (8.7) <0.001
Clinical outcome at follow-up, n (%)
Binary restenosis 8 (42.1) 99 (6.6) <0.001 13 (36.1) 61 (10.4) 0.006
TLR  9 (47.3) 93 (6.2) <0.001 15 (41.6) 40 (6.8) <0.001
Values are expressed as mean ± SD or n (%) of patients except follow-up duration.
ACC, American College of Cardiology; AHA, American Heart Association; AMI, acute myocardial infarction; BMI, body mass index; CABG, coronary artery bypass graft; CAD,
coronary artery disease; CTO, chronic total occlusion; DES, drug-eluting stents; IQR, interquartile range; LAD, left descending artery; LCX, left circumﬂex artery; LM, left main
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Fig. 3).
ndependent predictors of stent fracture
Fig. 4 summarizes independent predictors of SF in the newer
ES platforms. On multivariable logistic regression analysis, lesion
ngulation >45◦ (OR: 7.6; 95% conﬁdence interval [CI]: 2.2–26.3;
 = 0.001), RCA stenting (OR: 5.14; 95% CI: 1.62–16.3; p = 0.005),
nd total stent length (OR: 1.17; 95% CI: 1.03–1.33; p = 0.012) were
dentiﬁed as statistically signiﬁcant independent predictors of SF.
owever, stent design (closed-cell, i.e. Cypher Select®) did not
old as an independent predictor. In the CBX group, stent over-
ap (OR: 15.4; 95% CI: 5.67–42; p < 0.001), lesion angulation >45◦
OR: 9.42; 95% CI: 3.7–38; p = 0.001), and stent diameter (OR: 7.01;
5% CI: 1.19–41.4; p = 0.03) were identiﬁed as independent pre-
ictors (Supplementary Fig. 1). The calculated OR of CBX-to-neweright coronary artery; TLR, target lesion revascularization.
DES platforms for SF was 3.8 (95% CI: 1.86–7.8; p < 0.001) (data not
shown).
Discussion
This is the ﬁrst study to investigate incidence, clinical impact,
and independent predictors of fracture in newer DES platforms
which have been used widely in current clinical practice. The main
ﬁndings of our study are as follows. (1) The overall SF incidence of
the newer DES platforms was  signiﬁcantly lower than that of CBX.
(2) Binary restenosis and TLR rates for lesions with SF were much
higher than those for lesions without it. Notably, SF-related binary
restenosis and TLR rates were not different statistically between
the CBX group and the newer DES platforms’ group. (3) Stent-
ing on a bend >45◦, RCA stenting, and total stent length were the
independent predictors for fracture of newer DES platforms, while
closed-cell stent design (CS) was  not.
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Table  3
Comparisons of baseline characteristics between fracture subgroups in the newer DES platforms’ group and Cypher Bx group.
Clinical characteristics (n = no. of patients) Newer DES platformsFracture(+) (n = 18) Cypher BxFracture(+) (n = 36) p
Age, years 63.7 ± 10.5 67.9 ± 6.8 0.03
Male,  n (%) 13 (72.2) 24 (67) 0.82
BMI  (kg/m2) 24.1 ± 2.8 24.3 ± 1.9 0.84
Index  diagnosis, n (%)
Stable angina 10 (55.5) 20 (55.5) 0.98
Unstable angina 4 (22.2) 9 (25) 0.85
AMI  3 (16.6) 7 (19.4) 0.86
Silent  ischemia 2 (11.1) 0 (0) 0.23
Diagnosis at stent fracture detection, n (%)
Stable angina 6 (33.3) 13 (36) 0.8
Unstable angina 2 (11.1) 2 (5.5) 0.73
AMI  0 0
Asymptomatic 11 (61.1) 21 (58.3) 0.93
Diabetes mellitus, n (%) 5 (27.7) 11 (30.5) 0.93
Hypertension, n (%) 15 (83.3) 31 (86) 0.95
Current smoking, n (%) 6 (33.3) 9 (25) 0.5
Family history of CAD, n (%) 3 (16.6) 4 (11.1) 0.7
Previous MI, n (%) 5 (27.7) 4 (11.1) 0.16
Previous CABG, n (%) 1 (5.5) 0 (0) 0.97
LVEF  (%) 61 ± 7 59 ± 14 0.76
Median duration from index PCI to detection of SF, months (IQR) 12.5 (9.2–15.5) 9.5 (6.3–13) 0.11
Angiographic characteristics (n = no. of lesion) Newer DES platformsFracture(+) (n = 19) Cypher BxFracture(+) (n = 36) p
Target coronary artery, n (%) 0.45
LM  1 (5.2) 0 0.87
LAD  8 (42) 22 (61) 0.54
LCX  0 1 (2.7) 0.92
RCA 10 (52.6) 13 (36) 0.44
AHA/ACC type B2/C, n (%) 19 (100) 34 (94) 0.32
Reference diameter (mm) 3.18 ± 0.3 3.4 ± 0.3 0.03
Lesion  length (mm)  45.5 ± 16.2 36.5 ± 9.9 0.03
Diameter stenosis (%) 79 ± 24 75 ± 10 0.28
Lesion  angle >45◦ , n (%) 7 (36.8) 21 (58) 0.15
CTO,  n (%) 3 (15.8) 1 (2.7) 0.13
Multivessel CAD, n (%) 15 (78.9) 22 (61) 0.66
Stent  diameter (mm)  2.97 ± 0.32 3.18 ± 0.26 0.06
Maximum inﬂation pressure (atm) 14.3 ± 2.6 13.6 ± 2.5 0.4
Total  stent length (mm) 48.3 ± 16.8 41.2 ± 10.9 0.09
Number of stents per lesion 1.58 ± 0.6 1.53 ± 0.7 0.77
Stent  overlap, n (%) 11 (57.9) 19 (53) 0.6
Fracture type, n (%)
Partial 9 (47.4) 9 (25) 0.15
Complete 10 (52.6) 27 (75) 0.28
Fracture site, n (%)
Stent overlap area 10 (90.9) 20 (55.5) 0.06
Biggest angle at index CAG 12 (63) 31 (85) 0.12
Clinical outcome at follow-up, n (%)
Binary restenosis 8 (42.1) 13 (36.1) 0.52
TLR  9 (47.3) 15 (41.6) 0.2
Values are expressed as mean ± SD or n (%) of patients except follow-up duration from index PCI to detection of stent fracture.
ACC,  American College of Cardiology; AHA, American Heart Association; AMI, acute myocardial infarction; BMI, body mass index; CABG, coronary artery bypass graft; CAD,
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ain  coronary artery; LVEF, left ventricular ejection fraction; MI,  myocardial infarc
DES fracture is an uncommon phenomenon. Little is known
bout the exact incidence of SF in the “real-world” patient popu-
ation because it varies according to the type of population cohort,
ate of follow-up angiography, deﬁnition of SF, and most of the ear-
ier studies on SF focused on the initial platform of ﬁrst-generation
BX. Clinically reported incidence of fracture of CBX ranged from
.3% to 7.7% in previous observational studies [1–3], whereas data
n fracture of the initial platform of ﬁrst-generation paclitaxel-
luting stent (Taxus Express®) are rare. Nakazawa et al. reported a
igher frequency (29%) of DES fracture in 177 post-mortem coro-
ary lesions than those seen in previous clinical observational
tudies that utilized angiographic methods to detect SF [4].  This
ifference likely reﬂects the possibility that incidence of SF can be
nderestimated with imaging techniques used in clinical research
ompared with the methods for pathologic analysis of stents [5].
he newer platforms of DES have been upgraded compared withterquartile range; LAD, left descending artery; LCX, left circumﬂex artery; LM,  left
CA, right coronary artery; SF, stent fracture; TLR, target lesion revascularization.
initial platforms of ﬁrst-generation DES. The Cypher Select® stent
is composed of a slotted tube, closed cell, 316L stainless steel, mod-
iﬁed Bx VelocityTM stent with a longer undulating linker attached
to the center of the stent struts resulting in improved ﬂexibil-
ity, conformability and radial strength compared to the previous
Bx VelocityTM stent which had a shorter linker attached to the
end of stent crests. The Taxus® LibertéTM stent consists of a slot-
ted tube, open-cell, 316L stainless steel, LibertéTM stent with 3
different stent designs according to stent diameter. It has thin-
ner struts (0.0038 in.), smaller cell area, and more uniform strut
apposition than the previous Express2TM stent, which may provide
improved ﬂexibility, vessel coverage, and support. The Endeavor®stent consists of a laser-welded modular design, open-cell, thin-
strut (0.0036 in.), cobalt–chromium (MP35N), Driver® stent. The
XienceTM V stent consists of a slotted tube, open-cell, thin-strut
(0.0032 in.), cobalt–chromium (L605), Multi-Link VisionTM stent.
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Fig. 2. Incidence of binary restenosis and target lesion revascularization (TLR) in
the  newer DES platforms. Although incidences of binary restenosis and TLR among
the newer DES platforms were similar, those associated with stent fracture were
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Fig. 3. Incidence of binary restenosis and target lesion revascularization (TLR)
related with stent fracture in the Cypher Bx (CBX) group, the Cypher Select (CS) group
and the entire newer drug-eluting stents (DES) platforms’ group. Stent fracture-igniﬁcantly higher than those without it. SF, stent fracture subgroup; non-SF, non-
tent fracture subgroup; TLR, target lesion revascularization. CS, Cypher Select®; TL,
axus® LibertéTM; EN, Endeavor®; XV, XienceTM V.
hese improvements in terms of mechanical and material prop-
rties of newer DES platforms may  be a theoretical explanation of
he signiﬁcant low incidence of SF which was shown in the present
tudy. Interestingly, no SF was found in patients implanted with
he EN stent in our study. The EN stent has a cobalt–chromium
lloy, thin-strut platform, and unique design (laser-welded modu-
ar design) which is different from that of other stents (slotted tube
esign). Recently, Enoki et al. provided the results of a fatigue test to
ompare the SF behavior using commercially available stents with
ifferent manufacturing methods (modular vs. slotted tube design)
nd materials (cobalt–chromium alloy vs. stainless steel) [6].  They
eported that stents with modular structure demonstrated better
ehavior than slotted tube ones in the tensile-compression fatigue
est, and stents made of cobalt alloy had a longer endurance due
o its better mechanical properties than stainless steel. In addi-
ion, clinical reporting of EN stent fracture is rare; to the best of
ur knowledge, it has been reported in only 3 cases [7–9]. These
ines of available evidence strongly support the results of our study.
lthough the SF incidence of newer DES platforms was  statisti-
ally similar among stent types, the CS group showed numerically
Fig. 4. Independent predictors of fracture in the newrelated binary restenosis and TLR of the CBX group were not different compared
with those of the CS group and the entire newer DES platforms’ group. *Including
Cypher Select® .
higher occurrence than the others. It is well known that closed-cell
design stents are more rigid compared with open-cell design and
this can cause more vessel straightening after implantation, which
may  make the stent more prone to fracture as the countervailing
force of the vessel wall tends to revert the vessel axis to its origi-
nal shape [10]. Furthermore, CS stent struts are more radio-opaque,
making it easier to detect SF angiographically.
Patients with SF may  remain asymptomatic or may present with
an MI  suggestive of stent thrombosis or recurrent angina sugges-
tive of clinical restenosis [2,11,12]. In this study, a large portion
of patients with SF were asymptomatic irrespective of stent type.
The binary restenosis and TLR related with SF were much higher
compared with those related with non-SF in both CBX group and
newer DES platforms’ group, which is in keeping with the ﬁndings
of previous reports [2,3,13]. Moreover, it is notable that SF-related
binary restenosis and TLR rates of the newer DES platforms’ group
were similar to those of the CBX group. These ﬁndings may  imply
that clinical outcomes of SF remain not so favorable despite use
of newer DES platforms which may  lower the incidence of SF. The
angiographic pattern of restenosis in all patients with SF was focal,
er DES platforms. RCA, right coronary artery.
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incidental ﬁnding or a signiﬁcant marker of clinical in-stent restenosis. CatheterM.-W. Park et al. / Journal o
hich is consistent with the ﬁndings of several previous stud-
es [1,3,13]. For the mechanism showing how focal restenosis is
elated to SF, it has been suggested that lower drug delivery at
he fracture site may  not be effective in suppressing neointimal
yperplasia and an increase in local mechanical irritation by the
ractured struts can cause smooth muscle proliferation and inhibit
e-endothelialization, resulting in focal in-stent restenosis [13,14].
Features that have been associated with susceptibility to SF
n previous studies include long stent, RCA stenting, stent design
closed-cell design), overlapping stent, and excessive vessel angu-
ation [1,3,15,16]. Consistent with these reports, total stent length,
esion angulation >45◦, and RCA stenting were signiﬁcant predic-
ors for fracture of newer DES platforms in the present study.
imilar to the observations in several reports [3,14,15], all SFs of
ewer DES platforms occurred in long stented lesions, i.e. ≥28 mm,
ith a mean stent length of 48.3 mm.  Longer stents compared with
horter ones can be more prone to fracture owing to higher radial
orces [14]. Additionally, SF is relatively common at the “hinge”
oint where the mechanical stress to stent strut is greatest. The
verlapped stent edge and an excessive angle (lesion angulation
45◦) on the initial CAG can work as hinges [17]. Out of 19 fractures
f newer DES platforms, 15 SFs were located at the hinge point
hich was adjacent to the edge of overlapped stent (10 cases) or
he biggest angle (12 cases) on initial CAG. In the present study,
owever, overlapping stent did not show statistically signiﬁcant
ssociation with the occurrence of fracture using multivariable
egression analysis after adjusting for several confounders, while
t showed statistically signiﬁcant association with stent fracture
sing univariable regression analysis (unadjusted HR: 7.936; 95%
I: 3.07–20.5; p < 0.001). Finally, the RCA usually has greater curva-
ure and more vessel movement during the cardiac cycle than the
AD and LCX providing speciﬁc conditions that are more prone to
F. Considering ﬁndings of the present study, it is clear that pre-
ise evaluation of lesion characteristics remains very important to
redict SF, even in the era of newer DES platforms.
This study has several limitations that merit mention. First, the
uoroscopic and angiographic methods which were used to diag-
ose SF in our study, have a limited resolution power to detect
F compared with new technology such as the Stentboost (Philips
ealthcare, Best, Netherlands), which can show enhanced stent
trut shadows, and intravascular ultrasound was  not mandatory.
hus, our study may  have underestimated the frequency of SF.
owever, we tried to overcome this resolution limitation using
dditional detection methods such as increased magniﬁcation,
mage without contrast and image with inverted color. Second,
he deﬁnition of newer DES platforms may  seem arbitrary. In gen-
ral, all platforms of Cypher and Taxus stents are considered as a
ame ﬁrst-generation DES. However, although platforms of Cypher
elect® and Taxus® LibertéTM were improved from the initial ones,
ittle was known about clinical data on SF of these newer plat-
orms. Thus, we sought to evaluate the impact of the newer DES
latforms which have been used widely in current practice on SF
nd therefore, Cypher Select® and Taxus® LibertéTM were catego-
ized into the newer DES platforms’ group. As a result, we could
bserve a signiﬁcant difference in the SF incidence between the CBX
roup and the newer DES platforms’ group. Third, among newer
ES platforms, enrolled lesion numbers of the EN group were rel-
tively small. This may  act as an unintended bias to evaluate true
ncidence of SF of EN. Fourth, the study design was  a retrospective
nalysis; therefore, it is subject to the limitations inherent to all
uch analyses.
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In conclusion, this study shows that implantation of newer DES
platforms might reduce incidence of SF compared with CBX. How-
ever, when SF occurs, the rates of binary restenosis and TLR remain
similarly high. Lesion characteristics on index PCI are more impor-
tant than the type of implanted stent to predict SF in the newer DES
platforms’ era.
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